Abstract:The aim of this review was to describe the different ultrasonic modalities to non-invasively evaluate right cardiac chambers and pulmonary vascular bed function. M-Mode, 2-D, conventional pulsed doppler, tissue doppler imaging (TDI), strain rate imaging (SRI) and 3D echocardiography are illustrated in order to obtain both regional and global right heart and pulmonary function. The results have a good correlation with other invasive and non-invasive diagnostic techniques, as magnetic resonance imaging (MRI). Al… Show more
“…Increased E/e’ values correspond to increased RV filling pressures. It has been shown by right heart catheterization studies that there is a direct correlation between E/e’, right atrial volume and RV diastolic filling pressures (26). In our study, E/e’ ratio was increased after trastuzumab treatment.…”
Objective:Left ventricular (LV) dysfunction after trastuzumab treatment in erb-2 breast cancer cases has been fully investigated. However, there is not enough data about the effect of trastuzumab treatment on right ventricular (RV) functions. This study is designed to evaluate the right heart changes by performing echocardiography after trastuzumab treatment in patients with erb-2 breast cancer.Methods:Forty-two consecutive breast cancer patients with erb-2 overexpression mean age 50.4±11.6 years who were decided to receive trastuzumab treatment were enrolled. Echocardiographic examinations including 2-D, spectral, and tissue Doppler measurements were performed at the baseline (T1) and repeated after 6 months (T2).Results:Tricuspid annular plane systolic excursion (TAPSE) was decreased, RV myocardial performance index (RVMPI) and tricuspid E/e’ ratio was increased after trastuzumab treatment (1.84 vs. 2.14; p<0.01) (0.46 vs. 0.56, p<0.01) (4.4±1.07 vs. 5.08±1.46; p=0.04). Median serum NT-ProBNP levels, troponin I, and hs-CRP levels were similar between the groups. LVEF and TAPSE were negatively correlated with dosage of trastuzumab (r=-0.392, p=0.04; r=-0.522, p=0.006). There was a stepwise decrease in LVEF when trastuzumab used with anthracyclines however this not reached statically significant (62.4±2, 60±4.5; p=0.06).Conclusion:In our study; we observed a trend of RV deterioration after trastuzumab treatment. These preliminary RV changes were demonstrated by using TAPSE, RV tissue Doppler imaging derived MPI and E/e’ ratio parameters by echocardiography and these parameters could also use as markers of trastuzumab toxicity in this population.
“…Increased E/e’ values correspond to increased RV filling pressures. It has been shown by right heart catheterization studies that there is a direct correlation between E/e’, right atrial volume and RV diastolic filling pressures (26). In our study, E/e’ ratio was increased after trastuzumab treatment.…”
Objective:Left ventricular (LV) dysfunction after trastuzumab treatment in erb-2 breast cancer cases has been fully investigated. However, there is not enough data about the effect of trastuzumab treatment on right ventricular (RV) functions. This study is designed to evaluate the right heart changes by performing echocardiography after trastuzumab treatment in patients with erb-2 breast cancer.Methods:Forty-two consecutive breast cancer patients with erb-2 overexpression mean age 50.4±11.6 years who were decided to receive trastuzumab treatment were enrolled. Echocardiographic examinations including 2-D, spectral, and tissue Doppler measurements were performed at the baseline (T1) and repeated after 6 months (T2).Results:Tricuspid annular plane systolic excursion (TAPSE) was decreased, RV myocardial performance index (RVMPI) and tricuspid E/e’ ratio was increased after trastuzumab treatment (1.84 vs. 2.14; p<0.01) (0.46 vs. 0.56, p<0.01) (4.4±1.07 vs. 5.08±1.46; p=0.04). Median serum NT-ProBNP levels, troponin I, and hs-CRP levels were similar between the groups. LVEF and TAPSE were negatively correlated with dosage of trastuzumab (r=-0.392, p=0.04; r=-0.522, p=0.006). There was a stepwise decrease in LVEF when trastuzumab used with anthracyclines however this not reached statically significant (62.4±2, 60±4.5; p=0.06).Conclusion:In our study; we observed a trend of RV deterioration after trastuzumab treatment. These preliminary RV changes were demonstrated by using TAPSE, RV tissue Doppler imaging derived MPI and E/e’ ratio parameters by echocardiography and these parameters could also use as markers of trastuzumab toxicity in this population.
“…The relationship between ATH and other diseases such as cardiovascular and pulmonary disorders was reported in previous studies [1][2][3][4]. It is well known that ATH is one of the most common causes of upper respiratory tract obstruction, obstructive sleep apnea (OSA) and hypoxia in children [2].…”
Section: Introductionmentioning
confidence: 83%
“…RV MPI has been found to be clinically useful to define RV function [3]. MPI is a new echocardiographic parameter which correlates with invasive measurements and has been used to evaluate both systolic and diastolic functions.…”
Section: Discussionmentioning
confidence: 99%
“…It can be measured from the valve annulus with pulsed-wave TDE, and is not affected by cardiac rate, blood pressure, or ventricular geometry [26,27]. MPI is prolonged in patients with PH compared with normal subjects [3]. El-Damarawy et al [28] demonstrated that MPI had high efficacy, sensitivity and positively predicted values in defining RV dysfunction.…”
“…Echocardiographic assessment. Echocardiographic measurements were taken of the inner diameter of the RV and tricuspid annular plane systolic excursion (TAPSE) as previously reported (21).…”
Trimetazidine (TMZ) improves left ventricular (LV) function and alleviates angina. TMZ is a metabolism-related drug, but its molecular actions and non-metabolic effects have not yet been elucidated. In this study, we investigated whether TMZ improves right ventricular (RV) function and decreases apoptosis in RV myocardial cells (RVMCs) by regulating miRNA-21 (miR-21) expression in vitro and in vivo. We used cultivated RVMCs and LV myocardial cells (LVMCs) and provided hypoxic stimulation for 24 h to induce MC apoptosis. RVMCs showed more severe apoptosis as indicated by terminal deoxynucleotidyl-transferase-mediated dUTP nick end-labeling (TUNEL) staining and caspase-3 protein and activity assays. The decrease in miR-21 expression was more dramatic in RVMCs. Subsequently, TMZ (10 µM) was added to the RVMCs prior to hypoxic stimulation. The TMZ-treated RVMCs showed less apoptosis and an increased expression of miR-21. The transfection of RVMCs with a miR-21-specific inhibitor weakened the protective effects of TMZ. To evaluate TMZ effectiveness in right heart failure, we used a combination treatment of hypoxia and the vascular endothelial growth factor receptor blocker, Su5416, to construct a stable model, and administered TMZ. TMZ improved RV function (as indicated by an increase in tricuspid annular plane systolic excursion), and inhibited fibrosis. TMZ also protects RVMCs againts apoptosis and increases miR-21 expression.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.